Introduction
Respiratory systems are exposed to reactive oxygen species (ROS) from sources such as cigarette smoke, air pollution and indoor cooking/heating fires [1] . Interindividual differences in the blood levels of ROS scavengers may partially explain differences in the susceptibility to smoking-related respiratory disease [2] .
Bilirubin is the yellow-coloured end product of the haem catabolism pathway in mammals. The enzyme haem oxygenase generates an insoluble form of bilirubin from haem that is transported to the liver and is converted to a water-soluble (conjugated) form by the enzyme uridine diphosphate-glucuronosyltransferase (UGT1A1). Potent cytoprotective properties including antioxidant have been reported for both the unconjugated and conjugated forms of bilirubin [3, 4] . Various lines of experimental evidence mainly involving animal models suggest a role for serum bilirubin in protecting respiratory tissues against environmental stressors [5] . For example, bilirubin infusions can protect against bleomycin-induced pulmonary fibrosis in rats [6] . Cohort studies have reported lower rates of respiratory diseases and increased respiratory function in people with comparatively higher serum bilirubin levels after accounting for important confounders including smoking status [7] [8] [9] . However reverse causation where the disease process alters bilirubin levels or residual confounding by unmeasured confounders could potentially explain these relationships.
Genome wide association studies have repeatedly identified UGT1A1 as the major genetic locus underlying bilirubin levels in European, East Asian and African populations [10] [11] [12] . The UGT1A1 rs8175347 thymine-adenine (TA) polymorphism of the TATA box regulatory motif is well characterized in European populations since homozygosity for a low expresser variant ([TA]7 or [TA]8 repeats vs.
[TA]5 or [TA]6) underlies a common form of familial unconjugated hyperbilirubinaemia (Gilbert's syndrome; OMIM 143500) [13] . Finding an association between this common promoter variation, causing unconjugated hyperbilirubinaemia, and improved respiratory health could support a protective role for bilirubin previously suggested by animal experiments and observational studies in humans [14] . Unlike disease association studies using serum bilirubin levels, the potential for association being due to reverse causation is low because the UGT1A1 genotype is determined at birth and unaffected by the disease process. The random allocation of parental alleles at conception should in principle balance observed and unobserved confounders across genotype groups reducing the potential for residual confounding. This type of genetic association study is sometimes termed ''Mendelian randomization'' although causal inference using this design relies on some important assumptions [14] .
In the present study, we used data from the Medical Research Council (MRC) National Survey of Health and Development (NSHD), commonly known as the 1946 British birth cohort study, to investigate the relationship between a genetic variation in UGT1A1, underlying Gilbert's syndrome, and adult respiratory health as well as interactions with age and smoking status.
Patients and methods

Study population
The NSHD is the longest continuously running birth cohort in the world with details on sampling strategy, data collections, attrition and representativeness reported elsewhere [15] [16] [17] . In brief, the NSHD comprises a socially stratified sample of 5362 births out of a total of 16,695 registered in England, Wales and Scotland in one week in the year 1946 [16, 18] . The cohort includes all singleton births to wives of non-manual and agricultural workers and 1 in 4 singleton births to wives of manual workers. The cohort participants have been followed since birth with the most recent contact phase between the ages of 60 and 64 [15] . At age 53, 3035 of the original cohort were invited to provide a DNA sample. Contact was not attempted for individuals who had already died (n = 476), were living abroad (n = 583), had previously refused to take part (n = 648), or were untraced since the last contact at 43 years (n = 266). The sociodemographic features of the participants at ages 43 and 53 were broadly representative of the British post-war generation compared with the 1991 England Census data for the national population but with some over-representation of the widowed, or married women and men with lower educational attainment [17] . The sociodemographic features of participants at ages 60-64 appear to be similar to the 2001 England Census reference population, although there were lower levels of home ownership and limiting illness [15] . The cohort participants were selected prior to major immigration flows and so white British ethnicity is over-represented relative to the UK adult population. Additional details on the cohort, including numbers lost to follow-up at various contact phases with reasons, are included in the Supplementary Patients and methods section. DNA was obtained and successfully extracted from blood and/or buccal samples for 2939 out of the 3035 participants at age 53 [18] The study protocol was approved by the Medical Research and Ethics Committee (approval reference MREC 98/2/121 and MREC 07/H1008/168).
Variant selection and genotyping
The UGT1A1 rs8175347 (TA)5-8 repeat variant of the TATA box motif and the rs4124874 c.-3279T>G SNP of the phenobarbital enhancer module (PBREM) were selected for testing because these two loci have good evidence of regulatory function and explain around 40-45% of the estimated variation in bilirubin levels in healthy Europeans [19] [20] [21] [22] [23] . Although these two loci are in a fairly strong linkage disequilibrium (r 2 = 0.67) independent effects of the PBREM SNP over the (TA)n repeat on serum bilirubin levels have been reported [19] . The UGT1A1 (TA)n repeat was assayed using buccal samples (n = 2939) by a previously reported size-separation technique using high-percentage polyacrylamide gels [24] . The KASPar system by LGC Genomics, UK (http://www.lgcgenomics.com), was used to type the PBREM SNP using blood samples (n = 2718). Call rates were >95% for each variant. The presence of respiratory disease was defined as either having chronic obstructive pulmonary disease (COPD), asthma or a respiratory drug prescription at any of the follow-up time points. Moderate to severe COPD was spirometrically defined as a predicted FEV1 below 80% and a FEV1/FVC ratio below 0.7 (i.e. Global initiative for chronic obstructive lung disease stage 2 or higher). Predicted FEV1 was estimated using published algorithms derived from the British population [25] . Presence of an asthma diagnosis was based on the participant reporting recurring asthma at age 43 or clinically diagnosed asthma at age 53. Reports of asthma were not collected at ages 60-64. Respiratory drug use was defined as a self-reported prescription of bronchodilators, corticosteroids, cromoglycate, oxygen or mucolytics at ages 43, 53 or 60-64 years.
Statistical analyses
Mixed linear regression models, using a random subject effect to account for multiple measures in the same participants, were used to examine the relationship between genotypes and mean respiratory function. The models included a random intercept and random slope for age, specifying an unstructured covariance matrix. We categorized the common genotypes as high expresser group 0 (homozygous TA6), intermediate expresser group 1 (heterozygotes) and low expresser group 2 (homozygous TA7) [22, 23] . The rare (TA)5 allele was treated as (TA)6, and (TA)8 as (TA)7 in the genotype categories [22, 23] . Based on existing literature, the effect of this locus on bilirubin levels does not conform to the additive genetic model with levels for group 1 only slightly higher than group 0 but approximately double for group 2 vs. either group 0 or 1. Thus, we fitted the locus as a three level categorical variable and compared this with a simpler (recessive) model with group 2 vs. groups 0/1. The UGT1A1 PBREM SNP (rs4124874) was categorized as high expressers (homozygous T), intermediate expressers (heterozygotes) and low expressers (homozygous G), based on existing literature and the SNP was included as a three level variable to test for any independent effect on respiratory function over the (TA)n locus. Regression models initially included important predictors of respiratory function, which were age (continuous), sex, smoking status, height (continuous), and region of birth. Further details on how these variables were measured are included in the Supplementary Patients and methods. Although there is no prior evidence to suspect these variables would differ by genotype they are important predictors of the respiratory outcome and as such could improve the precision of estimation for other covariates in the regression models [26] . Previous studies have reported that the importance of genetic influences on respiratory function may become weaker with age [27] and stronger in the presence of ROS exposure [28] [29] [30] and thus, in a pre-specified analysis we tested for interactions between UGT1A1 variation, age and smoking status. If any significant interactions were identified, stratified analyses were performed. Statistical significance of categorical variables in regression models including genotypes and interactions with genotypes were tested using the Wald test. The PBREM SNP was added to the models already containing (TA)n genotypes and the Wald test was used to test whether this locus exhibited an independent effect over (TA)n.
A discrete-time proportional odds survival model was fitted to estimate the risk of respiratory disease across genotypes. The three time periods were included as dummy variables in the model (birth to age 43, age 43 to 53, and age 53 to age 60-64) and a random subject effect was included to account for multiple observation periods in the same participants.
Mendelian randomization is a form of instrumental variable analysis for causal inference using observational data [14, 31] . The phenotype of interest (i.e. serum bilirubin levels) is 'instrumented' using the genotype (i.e. UGT1A1 genotypes) to identify and attempt to quantify the genetic component of the variation and thus any causal relationships. Serum bilirubin measures were available for ages 60-64 and these were used in a two-stage instrumental variable analysis to further examine and quantify any causal relationships. Due to lower statistical power and potential for bias from respiratory data missing at this collection point (Supplementary Table 1) , the results are included in the Supplementary data section as a supportive analysis.
All analyses were carried out using Stata version 12.1. Probability values of less than 5% (p <0.05) were considered statistically significant assuming a twosided alternative hypothesis. A higher threshold of less than 10% (p <0.1) was used for detecting potential interaction effects.
Results
In total, complete genotype, respiratory function and covariate data were available for 2190 participants at age 53 when the DNA sample was taken (Fig. 1) . The minor allele frequencies for the (TA)n repeat variant (rs8175347) and the PBREM SNP (rs4124874) loci were 0.30 (7 or 8 TA repeats) and 0.43 respectively (Table 1) . Consistent with existing literature, serum bilirubin levels measured in a subgroup of participants, remaining in the cohort at ages 60-64, were highest in participants with the UGT1A1 (TA)n genotype associated with Gilbert's syndrome (Supplementary Patients and methods and Table 1) .
Mean FEV1 and FVC was higher for the (TA)n genotype associated with Gilbert's syndrome (group 2; [TA]7/7) with a suggestion that the relationship was stronger in heavy smokers at older ages ( Table 2 , Fig. 2 ). Never and ex-smokers at age 36 were pooled because there were no significant differences in respiratory function between these groups. There were no statistically significant univariable associations between UGT1A1 variation and important predictors of respiratory function including sex, height, smoking status and region of birth.
The (TA)n genotype underlying Gilbert's syndrome (group 2; [TA]7/7) was associated with significantly higher FEV1 (p <0.001) and FVC (p = 0.006) in the overall linear mixed model, including available respiratory data for all ages (Supplementary Table 2 ). There was no strong indication that respiratory function was lower in the UGT1A1 high expresser category (group 0) vs. the intermediate category (group 1) so we collapsed these into one group for further analyses. The PBREM SNP was not independently related to respiratory function in this mixed linear model after accounting for the (TA)n variation. There was evidence of a genetic interaction with age and smoking status, and thus cross-sectional regression analyses were performed (Table 3) .
Active participants at age 53 n = 3035 DNA successfully extracted from blood or buccal n = 2939 UGT1A1 (TA)n (rs8175347) call rates n = 2821
Complete smoking history including intensity n = 2364 Overall, the results suggest that the genetic effects on respiratory function become weaker in never/ex-smokers as cohort members age, whereas for heavy smokers the genetic effect seemed to be stronger at older ages. At age 43, the differences in respiratory function between (TA)n groups were fairly similar across smoking categories although there was a suggestion that the magnitude of the difference was greater for heavy smokers (Table 3) . At age 53 mean FEV1 was 409 ml higher (p <0.001) in heavy smokers and FVC was 530 ml higher (p <0.001) for those with the genotype underlying Gilbert's syndrome (group 2;
[TA]7/7) compared to those without this genotype, whereas the differences for other smoking categories at this age were weaker and non-significant (Table 3 ). The genetic associations at age 60-64 were also stronger for heavy smokers compared with age 43 but statistical power was lower due to a smaller sample size ( Table 3) .
Examination of the possible independent association of the PBREM SNP (rs4124874) with respiratory function, after adjustment for the effect of (TA)n showed evidence of some residual effect in heavy smokers at age 53 (p = 0.05 for FEV1 and p = 0.02 for FVC). Mean FEV1 in heterozygotes was 203 ml higher (95%; 0 to 407 ml) and mean FVC was 173 ml higher (95%; À1 to 426 ml) compared with homozygotes for the high expresser allele (data not shown). Including both loci in the regression models for heavy smokers at age 53, increased the explainable variability (R 2 ) in respiratory function by 9% for FEV1 and 8% for FVC. For comparison, the amount of variability explained by differences in height for this group was 13% for FEV1 and 16% for FVC.
The genotype underling Gilbert's syndrome (group 2; [TA]7/7) was associated with 50% lower odds of overall respiratory disease Total numbers with percentages (in parentheses) are reported for categorical variables and means with ± 1 standard deviation (in parentheses) for continuous variables (height measured in cm and FEV1 and FVC in litres). FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity. ⁄ Group 0 = (TA)5/6 or (TA)6/6; Group 1 = (TA)5/7, (TA)6/7, (TA)6/8; Group 2 = (TA)7/7 (underlying Gilbert's syndrome).
( Table 4 ). The effect sizes were similar across COPD, asthma and respiratory drug prescriptions (Table 4) . Interactions with smoking status were suggested but were not statistically significant possibly due to lower power for this binary outcome relative to continuous respiratory function.
The instrumental variable analysis including respiratory measurements at all ages and serum bilirubin measures estimated that a 10% increase in serum bilirubin levels was associated with an average 13 ml increase in both FEV (95% CI 4-22 ml; p = 0.007) and FVC (95% CI 2-24 ml; p = 0.02) (Supplementary Tables 3 and  4 ). The relationships were strongest in heavy smokers at age 53 with a 10% increase in serum bilirubin level associated with an average 77 ml increase in FEV (95% CI 35-119 ml; p <0.001) and a 79 ml increase in FVC (95% CI 28-130 ml; p = 0.002) (Supplementary Tables 3 and 4) .
Excluding the small number of participants with rare (TA)5 or (TA)8 alleles had no impact on any of the relationships examined.
Discussion
In the present study, we have shown that participants in the 1946 British birth cohort predisposed to Gilbert's syndrome due to low expression of the enzyme UGT1A1 have higher respiratory function and lower rates of respiratory disease relative to those without this predisposition. The genetic relationships seemed to be strongest amongst heavy smokers after age 43. The similar magnitude of the effect on FEV1 and FVC suggests that UGT1A1 and unconjugated bilirubin may have a protective role for both obstructive and restrictive respiratory diseases. These results lend support to a causal relationship between raised serum unconjugated bilirubin and protection of the respiratory system against the harmful effects of heavy smoking and show the beneficial effect of Gilbert's syndrome in this context. This protective effect may extend to other environmental sources of oxidants as well as cigarette smoke such as air pollution and to protection from certain types of lung cancer.
To the best of our knowledge, the present study is the first to examine respiratory function and disease in people with the causal variant underlying Gilbert's syndrome and to show an interaction with smoking status. Another group recently reported associations between a SNP, linked to bilirubin levels from genome wide association studies and respiratory function in a Swiss cohort [9] . This study reported interactions with serum bilirubin and smoking status for the full cohort (n = 4195) but lacked power to examine genetic interactions with smoking for the subset with DNA (n = 982). Overall, the genetic effects appear slightly weaker than for our study although differences in age, smoking behaviour and the exclusion of patients with a history of asthma may explain these differences. Genetically reduced haem oxygenase 1 activity, resulting in lower bilirubin levels, has also been associated with poorer respiratory function and a higher risk of respiratory disease with the effect strongest in heavy smokers (P20 cigarettes per day) [32, 33] . However, pleiotropy is a possibility for those studies of haem oxygenase 1 where polymorphisms also lower the production of other products of the pathway that may influence respiratory function including carbon monoxide. Genetic variation of UGT1A1 has been associated with other diseases where oxidative stress is purported to play a pathophysiological role. For example, longitudinal studies with long-term follow-up, including the Framingham Offspring cohort study, have reported 50-80% lower rates of cardiovascular disease and mortality in people with UGT1A1 (TA)n genotype associated with Gilbert's syndrome or linked loci [34] [35] [36] . However, these relationships are not consistently replicated [37] .
The strengths of the current study include the long-term follow-up, allowing analysis of respiratory function over a 20-year period, standardized measurement of phenotypes and the use of a strong genetic instrument for bilirubin levels. Limitations include self-reported smoking status, asthma and drug use, and the spirometric definition of COPD without knowledge of symptoms. There may also be some sources of bias. For example, the genetic associations could have been diluted if participants with genetically lower bilirubin levels were more likely to drop out of the cohort before age 53 due to poor health or death before the DNA sample was taken. In the instrumental variable analysis, the stronger causal estimates using genetic instruments vs. regression coefficients from using serum bilirubin may suggest that the relationship between serum bilirubin measures and respiratory health are underestimated, due to factors such as regression dilution bias, model misspecification (assuming a linear relationship), reverse causation and negative confounding from drugs and disease processes. Certain antioxidant systems, including haem oxygenase 1 (the first step in bilirubin production), are upregulated in response to disease processes, suggesting that reverse causation is a possibility. Stronger causal estimates from genetic instrumental variable analyses vs. other study designs have also been reported with respect to low-density lipoprotein cholesterol and the risk of coronary heart disease [38] . The results of the study are broadly generalizable to the British post-war generation who were mainly of UK/northern European ancestry [17] but the relationships in non-European ethnic groups require further study. Finally, we have used an instrumental variable approach to support causality but this relies on some important assumptions, including absence of confounding by pleiotropy (genes affecting multiple traits), linkage disequilibrium (where due to co-inheritance the variant under study may be a proxy for the causal variant or confounded by a linked variant), and population stratification (spurious associations due to ancestry differences, for example associated with geographic differences in genotype frequencies across study groups) [14] . The 1946 Birth cohort is predominantly white European and we adjusted for possible geographic effects to reduce any potential genetic stratification. The UGT1A1 gene is located in a gene complex that encodes several other UGT1A isoforms involved in glucuronidation of many other endogenous and exogenous molecules. A region of linkage disequilibrium exists across the complex and encompasses other variants with purported function [39] . Thus, it is plausible that the relationships in the present study reflect substrate effects of a different UGT1A isoform although there are no biologically plausible candidates that we are aware of at present. A further complexity is that antioxidants can increase UGT1A1 expression as the result of interactions of a signalling pathway, involving the transcription factor Nrf2 via regulatory elements, which overlap with the PBREM region [40] . The amount of variability in respiratory function explained by the UGT1A1 variation in heavy smokers suggests a role in predicting adult respiratory outcomes and further research is required to investigate this empirically in larger independent cohorts. The results of the present study support but do not prove causality. Randomised controlled studies of the short-term effect of bilirubin infusions or drugs that specifically inhibit UGT1A1 activity on respiratory and endothelial function in humans are perhaps possible, with similar studies carried-out for another serum antioxidant, uric acid, suggesting a physiological benefit [41] .
The high frequency of various alleles causing mild hyperbilirubinaemia and Gilbert's syndrome across human populations, including a relatively common non-synonymous SNP of UGT1A1 in East Asian groups, has led to the speculation that there has been a balancing selection. One theory is that neurotoxicity, induced by very high bilirubin levels in neonates, prevents the alleles causing hyperbilirubinaemia from being more common across populations [42, 43] . It should be noted, however, that in certain regions of Equatorial Africa, UGT1A1 promoter alleles that cause Gilbert's syndrome in Europeans are more common than those associated with normal bilirubin levels [43] . Protection from cigarette and other smoke in the environment of adult modern humans may not have had much impact on reproductive Regression coefficients for models including sex, height, and birth region. Table 4 . Association between UGT1A1 rs8175347 (TA)n repeat variants and respiratory disease up to age 60-64 (COPD, asthma, or respiratory drug use) in a cohort of British adults followed since birth in 1946. outcome. Although laboratory research has focused on antioxidant properties of raised bilirubin, protection against respiratory infections, such as pneumonia and bronchitis is also a plausible explanation for the results of the present study [44] , and arguably a more compelling hypothesis for the high frequency of alleles causing mild hyperbilirubinaemia rather than protection against chronic late-onset diseases. The potential role of the UGT1A1 variation and bilirubin levels in the susceptibility to respiratory infections across the life course is an interesting topic for further research. In summary, a common genetic variation of the UGT1A1 gene, causing moderately raised bilirubin and Gilbert's syndrome, is associated with significantly higher respiratory function in adults with the strongest effects seen in heavy smokers, and lower rates of respiratory disease. This may reflect antioxidant or other protective properties of serum bilirubin. 
